Subsequently, analysis of gene expression data from more than 1000 types of cancer tissues revealed that the expression of CLCA2 was significantly reduced in bladder cancer, esophageal cancer, lung cancer, high-grade nasopharyngeal carcinoma, colorectal cancer, lymphoma tissue, and prostate cancer [63–68]. The gene discussed is CLCA2; the disease is lung carcinoma.